Palvella Therapeutics, Inc. PVLA
138.16
(7.91)
(5.42%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow PVLA
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(117.82%) | (92.10%) | (34.25%) | (46.63%) | |
| (74.02%) | (56.45%) | (28.73%) | (37.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.17%) | (87.56%) | (19.40%) | (25.59%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(2.30) | (2.22) | (2.22) | (2.54) | |
Free Cash Flow |
(25.47) | (25.01) | (29.10) | (36.51) | |
| Other line items | |||||
Cash ROIC |
(24.91%) | (29.09%) | (5.89%) | (7.81%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.60 | 0.59 | 0.59 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.30) | (2.22) | (2.22) | (2.54) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates